Literature DB >> 11796829

Abnormal iron deposition in renal cells in the rat with chronic angiotensin II administration.

Nobukazu Ishizaka1, Toru Aizawa, Ieharu Yamazaki, Shin-ichi Usui, Ichiro Mori, Kiyoshi Kurokawa, Shiow-Shih Tang, Julie R Ingelfinger, Minoru Ohno, Ryozo Nagai.   

Abstract

Acute experimental iron loading causes iron to accumulate in the renal tissue. The accumulation of iron may play a role in enhancing oxidant-induced tubular injury by producing increased amounts of reactive oxygen species. From findings in cells from heme oxygenase-1 (HO-1)-deficient mice, HO-1 is postulated to prevent abnormal intracellular iron accumulation. Recently, it has been reported that HO-1 is induced in the renal tubular epithelial cells, in which iron is deposited after iron loading, and that this HO-1 induction may be involved in ameliorating iron-induced renal toxicity. We previously showed that chronic administration of angiotensin II to rats induces HO-1 expression in the tubular epithelial cells. These observations led us to investigate whether there is a link between iron deposition and HO-1 induction in renal tubular cells in rats undergoing angiotensin II infusion. In the present study, rats were given angiotensin II for continuously 7 days. Prussian blue staining revealed the distinct deposits of iron in the proximal tubular epithelial cells after angiotensin II administration. Electron microscopy demonstrated that iron particles were present in the lysosomes of these cells. Histologic and immunohistochemical analyses showed that stainable iron and immunoreactive ferritin and HO-1 were colocalized in the tubular epithelial cells. Treatment of angiotensin II-infused rats with an iron chelator, deferoxamine, blocked the abnormal iron deposition in kidneys and also the induced expression of HO-1 and ferritin expression. Furthermore, deferoxamine treatment suppressed the angiotensin II-induced increase in the urinary excretion of protein and N-acetyl-beta-D-glucosaminidase, a marker of tubular injury; however, deferoxamine did not affect the angiotensin II-induced decrease in glomerular filtration rate. These results suggest that angiotensin II causes renal injury, in part, by inducing the deposition of iron in the kidney.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796829     DOI: 10.1038/labinvest.3780398

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  5 in total

1.  Angiotensin II inhibits iron uptake and release in cultured neurons.

Authors:  Yong Liu; Suna Huang; Fang Du; Guang Yang; Li Rong Jiang; Chao Zhang; Zhong-ming Qian
Journal:  Neurochem Res       Date:  2014-03-30       Impact factor: 3.996

2.  Angiotensin II alters the expression of duodenal iron transporters, hepatic hepcidin, and body iron distribution in mice.

Authors:  Soichiro Tajima; Yasumasa Ikeda; Hideaki Enomoto; Mizuki Imao; Yuya Horinouchi; Yuki Izawa-Ishizawa; Yoshitaka Kihira; Licht Miyamoto; Keisuke Ishizawa; Koichiro Tsuchiya; Toshiaki Tamaki
Journal:  Eur J Nutr       Date:  2014-08-07       Impact factor: 5.614

3.  Protective Role of Silymarin and Deferoxamine Against Iron Dextran-induced Renal Iron Deposition in Male Rats.

Authors:  Mehdi Nematbakhsh; Zahra Pezeshki; Behjat Alsaadat Moaeidi; Fatemeh Eshraghi-Jazi; Ardeshir Talebi; Hamid Nasri; Shahrzad Baradaran; Marjan Gharagozloo; Tahereh Safari; Maryam Haghighi
Journal:  Int J Prev Med       Date:  2013-03

4.  Chronic Hematuria Increases Chronic Kidney Injury and Epithelial-Mesenchymal Transition in 5/6 Nephrectomy Rats.

Authors:  Min Xiao; Ajay K Medipally; Laura Biederman; Anjali A Satoskar; Iouri Ivanov; Brad H Rovin; Sergey V Brodsky
Journal:  Front Med (Lausanne)       Date:  2021-11-25

5.  Iron chelation suppresses secondary bleeding after intracerebral hemorrhage in angiotensin II-infused mice.

Authors:  Jie Wang; Xiao-Qin Tang; Min Xia; Cheng-Cheng Li; Chao Guo; Hong-Fei Ge; Yi Yin; Bo Wang; Wei-Xiang Chen; Hua Feng
Journal:  CNS Neurosci Ther       Date:  2021-08-04       Impact factor: 5.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.